In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intrexon Corp.

www.dna.com

Latest From Intrexon Corp.

Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen

The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.

Financing Deals

Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy

Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.

Deals Commercial

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 

Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Diversified
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • RheoGene Inc.
  • Genomatix Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intrexon Corp.
  • Senior Management
  • Randal J Kirk, Chmn. & CEO
    Rick Sterling, CFO
    Thomas D Reed, PhD, CSO
    Andrew J Last, COO
  • Contact Info
  • Intrexon Corp.
    Phone: (301) 556-9900
    20358 Seneca Meadows Parkway
    Germantown, MD 20876
    USA
UsernamePublicRestriction

Register